Yirui Wang; Mianli Bian; Yujinpeng Hao; Jun Shao

doi:10.19080/GJPPS.2026.12.555847

Opinion

Generic Sugammadex: Therapeutic Equivalence, Clinical Practice, and the Real Questions we should be asking

>Jonathan Vaughn, DHA, MSN, CRNA*

University of Mississippi Medical Center School of Nursing, Nurse Anesthesia Program, Jackson, Mississippi

Submission:September 16, 2026;Published:September 23, 2026

*Corresponding author: Jonathan Vaughn, DHA, MSN, CRNA, University of Mississippi Medical Center School of Nursing, Nurse Anesthesia Program, Jackson, Mississippi

How to cite this article: Jonathan V. Generic Sugammadex: Therapeutic Equivalence, Clinical Practice, and the Real Questions we should be asking. 002 Glob J Pharmaceu Sci. 2026; 12(5): 555847. DOI: 10.19080/GJPPS.2026.12.555847.

Background

Sugammadex has become a staple in most anesthesia providers’ formulary since its introduction to clinical practice in the United States in 2015. Sugammadex quickly earned a spot in the anesthesia providers’ toolbox due to its rapid and predictable reversal of neuromuscular blockade induced by Rocuronium and Vecuronium [1]. Sugammadex superior clinical benefits are settled: reduced postoperative residual neuromuscular blockade, faster recovery to spontaneous ventilation compared to traditional acetylcholinesterase inhibitors, decreased perioperative complications including postoperative nausea and vomiting, and improved patient outcomes [2-4]. Bridion (Merck’s Sugammadex) has had exclusive market availability in the United States for almost a decade, making it the only option for perioperative neuromuscular blockade reversal in this drug class.

In 2026, the Food and Drug Administration (FDA) approved two generic Sugammadex formulations: B. Braun’s generic Sugammadex (200 mg/2 mL), approved July 2026, and Lupin’s generic Sugammadex, available in both 200 mg/2 mL and 500 mg/5 mL, approved August 2026 [5,6]. Both B. Braun and Lupin’s generic Sugammadex formulations carry a therapeutic equivalence rating similar to Bridion, meaning both drugs are bioequivalent and pharmacologically close to the same. Yet, providers responsible for patient care and patient outcomes may have clinically relevant questions that therapeutic equivalence data cannot answer.

The Promise and Reality of Generic Equivalence

The generic Sugammadex drugs gaining FDA approval as therapeutically equivalent to Bridion reflect thorough and rigid bioavailability and bioequivalence studies that demonstrated that the generic formulations achieve similar plasma concentrations and pharmacokinetic profiles in healthy volunteers under controlled conditions [5,6]. This important achievement of FDA approval represents sound pharmaceutical science. This step in FDA approval aligns with sound public health policy for patients. Good public health policy for patients leads to increased access and decreased cost. Thus, the goal of any generic drug is to expand access and reduce costs to patients, while maintaining efficiency and safety.

Even with FDA approval as therapeutically equivalent to Bridion, this may not address all the clinically relevant questions providers have. Typically, bioequivalence studies are conducted in fasted, healthy volunteers under standardized conditions, often using single-dose administrations [7]. The perioperative area presents with many different challenges: patients are often elderly, receiving multiple medications concurrently that may alter drug pharmacodynamics or pharmacokinetics, hemodynamically compromised, hypothermic, and with multiple comorbidities. Also, patients present with variations in body composition, individual sensitivity to neuromuscular blocking agents, and renal function. All these patient challenges and variations can introduce variability in drug effect that exists independent of which manufacturer supplies the Sugammadex [8].

Practical Considerations for Perioperative Practice

The introduction of generic Sugammadex raises several considerations for the clinically practicing providers, particularly anesthesia providers and pharmacists:

Institutional standardization: Institutional dosing protocols are utilized by many pharmacies and anesthesia practices, based on the depth of neuromuscular blockade. Neuromuscular blockade is quantified using neuromuscular monitoring. Most institutional dosing protocols are approximately 4 mg/kg for deep neuromuscular blockade and 2 mg/kg for moderate blockade [2-4]. Many pharmacies and anesthesia practices will switch Sugammadex manufacturers due to cost pressures, inventory constraints, or formulary restrictions. Even though this change in manufacturers does not require dose adjustment, it introduces slight variations in vials that may warrant the provider's attention.

Formulary management and supply chain: With oral medications, patients may receive generic substitutions over time. With most oral, multi-dose medications, the patient receives long-term supplementation through medication adherence. Perioperative use of Sugammadex is a single, acute administration. With multiple Sugammadex manufacturers, any minor pharmacokinetic variation could be consequential to patient care. Thus, hospital pharmacists and anesthesia providers must navigate procurement decisions, single-dose vial format, and vial concentrations.

Clinical outcomes and monitoring: To date, there is a gap in the peer-reviewed literature on clinical studies that directly compare generic Sugammadex formulations with Bridion in the perioperative setting. While bioequivalence data support substitutability, pharmacists and anesthesia providers would like prospective outcome data from clinical practice that examines time to train-of-four recovery, postoperative complications, extubation readiness, and patient satisfaction. These studies would provide additional confidence in clinical substitutions.

The Broader Question: Are We Asking the Right Things?

With the entry of generic Sugammadex into the U.S. market, two potential benefits are greater access and cost containment. In clinical practice, the framing of this discussion should not revolve around price or chemical equivalence. The essential questions are:

a) Regarding our specific patient populations, do all three formulations (Bridion, Lupin, B. Braun) produce equivalent clinical outcomes? Therapeutic equivalence is necessary but may not be sufficient to answer this question.

b) What role should institutional standardization have in procurement and formulary decisions? Frequent switching between manufacturers introduces variables that complicate quality improvement and outcome tracking. Also, cost pressure is a real-world problem.

c) How does pharmacy communicate generic substitution to anesthesia providers?

d) Is there a role for prospective outcome monitoring or quality assurance registries, by pharmacy and anesthesia, as generic penetration increases? This would allow for the detection of any unanticipated differences in real-world practice.

Conclusion

Is generic Sugammadex as effective as Bridion? One could say it is almost certainly as effective as Bridion. The bioequivalence data and pharmacology support it. The question is, does the clinical outcome data support it too? Over time, I believe the clinical outcome data will support it too. “Almost certainly as effective” is not a standard that anesthesia providers should accept, and it should not be the standard that any provider accepts, either. Until real-world clinical outcome data exist, institutions and providers need a clear plan moving forward. That plan should actively monitor outcomes, communicate formulary changes, and build the infrastructure for pharmacy and anesthesia to catch problems early if they arise. Generic Sugammadex is sound. The question now is whether the systems around it are too.